Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- A person or their legal representative must be able to sign and date a consent form agreeing to take part.
- Participants must be willing to follow the study procedures and take part in the full research process.
- Adults aged 18 to 70 years, of any gender, including both people with cancer and healthy volunteers, may be considered.
- People who have been suspected of having or diagnosed with certain cancers — such as stomach cancer, pancreatic cancer, bile duct cancer, or oesophageal cancer — supported by test results such as blood markers, ultrasound, CT, MRI, or tissue examination, and who are in generally good health.
- Participants must meet specific laboratory test result requirements (confirm with trial site for exact details).
- Women who could become pregnant must have been using contraception for at least one month before the screening stage, and must agree to continue using contraception throughout the study and for a set period after it ends.
- There may be additional inclusion criteria not fully detailed here (confirm with trial site).
Who may not be able to join:
- People who are unable to complete a PET/MR or PET/CT scan, including those who cannot lie flat, or who experience claustrophobia or fear of radiation.
- People who have other existing medical conditions alongside the condition being studied (confirm with trial site for specifics).
- People who are known to be allergic to the imaging agent used in this study (targeted at CLDN18.2) or to its inactive ingredients; also, people whose blood sugar level is above 11.0 mmol/L before receiving the FDG imaging substance.
- People who have a history of taking certain other medications alongside the study treatment (confirm with trial site for specifics).
- People whom the research team considers unlikely to follow the study requirements reliably.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiaoli Lan, PhD, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phone: 0086-027-83692633
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Visual and standardized uptake values assessment of lesions and biodistribution
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.